Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Who Are Relapsed/Refractory/Resistant to Prior Therapies

Next Previous
Trial Profile

An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Who Are Relapsed/Refractory/Resistant to Prior Therapies

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs R 289 (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Rigel Pharmaceuticals

Most Recent Events

  • 07 Dec 2025 According to a Rigel Pharmaceuticals media release, 33 patients have been enrolled in the study, and the company looks forward to concluding the dose expansion phase and selecting the recommended phase 2 dose for future clinical studies in the second half of 2026.
  • 07 Dec 2025 Results presented in a Rigel Pharmaceuticals media release
  • 07 Dec 2025 According to a Rigel Pharmaceuticals media release, data from the ongoing phase 1b study, are being presented today in an oral session by Dr. Guillermo Garcia-Manero at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 6-9, in Orlando, Florida and virtually.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top